Marketing and advertising are crucial in pharmaceutical manufacturing, showcasing key finishes and disseminating information about drugs, conditions, and healthcare products to professionals and consumers. However, these activities face strict regulations and ethical concerns due to their significant impact on public health and safety. This paper examines the complex landscape of broadcasting and advertising in the pharmaceutical industry, focusing on the ethical and regulatory challenges faced by industry stakeholders. It begins with an overview of the fundamental laws governing drug billing and advertising, emphasizing the importance of honesty, transparency, and integrity in all marketing efforts. The paper then explores the regulatory framework overseeing drug promotion and sales, highlighting key guidelines set by bodies such as the FDA in the U.S. and the EMA in Europe. These regulations cover various aspects of drug marketing, including content requirements, risk and side effect disclosures, and interactions with healthcare professionals (Bailey, 2001). The paper discusses the impact of mathematical and public television rules, direct-toconsumer advertising, and personalized shopping trends. It argues that ethical issues shape drug marketing strategies, addressing overpromotion, misleading claims, and potential conflicts of interest. By examining the ethical and regulatory landscape, the paper provides insights into best practices for drug advertising, emphasizing compliance with regulations, adherence to ethical standards, and the commitment to providing balanced and accurate information to ensure the safe and effective use of pharmaceuticals.
Marketing, Advertising, Pharmaceutical Industry, Regulatory Compliance, Ethical Consideration, Drug Promotion, Healthcare Products, Consumer Safety.
Haider, R., Zehra, A., Mehdi, A., Das, G. K., Ahmed, Z., and Zameer, S. (2024). Advertising and Marketing within the Pharmaceutical Industry: Navigating Ethical and Regulatory-Demanding Situations. Dale View's Journal of Clinical Pharmacology and Pharmacotherapeutics, 1(1), 28-40.